MedPath

Is The Occurrence of IgA-Nephropathy modulated by Gene Mutations of Phase 1 and 2 Detoxification Enzymes?

Recruiting
Conditions
CKD with particular reference to IgA nephropathy
Registration Number
DRKS00012928
Lead Sponsor
Förderverein Nephrologie e.V.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
200
Inclusion Criteria

Histologic proven IgA nephropathy in Caucasians of either sex
For the controls: chronic kidney disease patients without glomerulonephritis in Caucasians of either sex
Further controls: published SNP- frequencies of phase I and II gene (rate of polymorphisms in the general population)

Exclusion Criteria

none

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Prevalences of genetic variants in enzymes of phase I and II will be assessed in patients with histologic proven IgA nephropathy. Genetic variants will be analysed by means of DNA from EDTA blood samples and set in comparison to the prevalence in chronic kidney disease patients without glomerulonephritis as well as to the published SNP (single nucleotide polymorphism) frequencies of data bases.
Secondary Outcome Measures
NameTimeMethod
Progression of the disease based on GFR in relation to the number of genetic variants
© Copyright 2025. All Rights Reserved by MedPath